Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > The Plan

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Mar 20, 2024 5:51pm

64 Views

Post# 35943793

RE:RE:RE:The Plan

Hey guys I don't disagree that we should reach out to Andrew and contact the CSA regarding this take-over. Go ahead and call Andrew that is your business.
What I don't appreciate is after 7+ years of keeping the mangement of this company's feet to the fire I get this type of "scolding" by a fellow shareholder. That is a number of years longer than most of the current posters.
This is a forum where we all get to voice our opinions. I voiced mine .

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”